A Study in Healthy Participants Investigating Biomarkers After Exposure to Heparin When Heparin is Administered in the Fasted State or After a High-fat Meal. Heparin, a Registered Drug, is an Anticoagulant (Blood Thinner) That Prevents the Formation of Blood Clots.

Inclusion Criteria: * Healthy subject * Male or female * 18 to 65 years, inclusive, at the time of signing informed consent * Body mass index:18.0 kg/m \^2 to 29.9 kg/m\^2, inclusive, at the time of signing informed consent * Body weight greater than or equal to 50 kg at the time of signing informed consent Exclusion criteria: * Using tobacco products within 60 days prior to the first drug administration. * Any kind of coagulation disorder or any first degree family members with major bleeding tendency. * History of anemia, thrombocytopenia, HIT, other blood disorders, or any clinically relevant bleeding (epistaxis). * Exposure to heparin (unfractionated heparin or low molecular weight heparin) within 100 days prior to the first dose of heparin. * Participation in any clinical study of an approved or non-approved investigational medicinal product within 30 days (or 5 half-lives of the investigational medicinal product, whichever is greater) before screening. If the half-life of the investigational medicinal product is unknown, subjects participating in a clinical trial in the 6 months prior to (the first) treatment administration will be excluded. * Any kind of coagulation disorder or any first degree family members with major bleeding tendency. * Unwillingness to consume the entire high-fat standardized meal (e.g. vegetarians, vegans and subjects who follow special diets).